Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
etrade deleted this message after they sent it to me, but I saved a copy
Sent: August 28, 2007 10:18 AM ET
Subject: Trading & Investing
Topic: Execution Status/Trade Inquiry
Account: XXXX
Message: why are $0.05's printing on OUTT and I have a sell order at 0.045..VERY SHADY AGAIN
Dear Mr. xxxx
As for your open oder on OUTT, unfortunately when trading a security in the OTC,
Pink Sheets, or a Penny Stock there is a significant risk that your order may
not get executed even when trades at or below your limit price have taken place.
This market is highly unregulated, and market makers are not required to execute
your order even if it is the best currently available. E*Trade Financial did
post your order to the market makers however none chose to execute your order.
If you still however feel you are due an execution then I will list the steps
you will need to take to process a trade inquiry.
To process this inquiry, please go to the following web address:
https://us.etrade.com/e/t/estation/help?id=xxxxxxxx
Once there, click on "Request the status of my trade executions". A trading
specialist will take a look at the activity during that time on the market in
order to determine a resolution. Please allow 1-4 business days for this
research to take place. Please be aware that the resolution of a trading inquiry
may take some time. During the time of research, you have the option to take
market action. Should you choose to take market action, which may limit your
losses, and if the trade inquiry comes back in your favor, your account may
receive some adjustment. However, if it does not come back in your favor, the
trade will stand as is. If you choose to leave your liability open, you may
incur additional damages. I cannot advise you as to which option you should
take. In the meantime, please let us know if you have any other questions or
concerns.
I hope this information has been helpful. Please let us know if we've addressed
your questions and concerns satisfactorily by taking a 30-second survey at the
following web address:
http://etradefinancialsurvey.com
As always, thank you for choosing E*TRADE Financial for your investing, banking
and lending needs. We encourage you to continue using the Help Center for any
assistance in the future. You are also welcome to call us at 1-800-ETRADE1
(800-387-2331) between 7AM and 12AM EST, seven days a week. International
customers please dial +1-678-624-6210.
Sincerely,
Damon Busboom
11:00 AM - 8:00 PM MST Mon-Fri
1-800-355-8888 ext 3032583
Financial Services Representative
ABOUT TIME ETRADE: (etrade deleted this message after they sent it to me, but I saved a copy)
Sent: August 28, 2007 10:18 AM ET
Subject: Trading & Investing
Topic: Execution Status/Trade Inquiry
Account: XXXX
Message: why are $0.05's printing on OUTT and I have a sell order at 0.045..VERY SHADY AGAIN
Dear Mr. xxxx
As for your open oder on OUTT, unfortunately when trading a security in the OTC,
Pink Sheets, or a Penny Stock there is a significant risk that your order may
not get executed even when trades at or below your limit price have taken place.
This market is highly unregulated, and market makers are not required to execute
your order even if it is the best currently available. E*Trade Financial did
post your order to the market makers however none chose to execute your order.
If you still however feel you are due an execution then I will list the steps
you will need to take to process a trade inquiry.
To process this inquiry, please go to the following web address:
https://us.etrade.com/e/t/estation/help?id=xxxxxxxx
Once there, click on "Request the status of my trade executions". A trading
specialist will take a look at the activity during that time on the market in
order to determine a resolution. Please allow 1-4 business days for this
research to take place. Please be aware that the resolution of a trading inquiry
may take some time. During the time of research, you have the option to take
market action. Should you choose to take market action, which may limit your
losses, and if the trade inquiry comes back in your favor, your account may
receive some adjustment. However, if it does not come back in your favor, the
trade will stand as is. If you choose to leave your liability open, you may
incur additional damages. I cannot advise you as to which option you should
take. In the meantime, please let us know if you have any other questions or
concerns.
I hope this information has been helpful. Please let us know if we've addressed
your questions and concerns satisfactorily by taking a 30-second survey at the
following web address:
http://etradefinancialsurvey.com
As always, thank you for choosing E*TRADE Financial for your investing, banking
and lending needs. We encourage you to continue using the Help Center for any
assistance in the future. You are also welcome to call us at 1-800-ETRADE1
(800-387-2331) between 7AM and 12AM EST, seven days a week. International
customers please dial +1-678-624-6210.
Sincerely,
Damon Busboom
11:00 AM - 8:00 PM MST Mon-Fri
1-800-355-8888 ext 3032583
Financial Services Representative
Accredited to Continue Lawsuit Against Lone Star
Friday August 31, 2:59 pm ET
Rejects Proposal To Re-Price At $8.50 Per Share
SAN DIEGO--(BUSINESS WIRE)--Accredited Home Lenders Holding Co. (NASDAQ:LEND - News; "Accredited" or "Company") announced today that it will continue to pursue its lawsuit against Lone Star Fund V (U.S.), L.P. and two of its affiliates ("Lone Star") seeking specific performance of Lone Star's obligations to close Lone Star's tender offer for the outstanding common stock of Accredited at $15.10 per share and to complete the merger with Accredited.
ADVERTISEMENT
Accredited noted that, on August 30, 2007, Lone Star disclosed that it has proposed to Accredited's Board of Directors to settle the lawsuit and reduce the offer price of $15.10 to $8.50 per share, a reduction of approximately 44%. As Accredited has previously announced and asserts in its lawsuit, Accredited believes that all conditions to closing of the tender offer at $15.10 per share were satisfied when more than 97% of Accredited's outstanding common stock was tendered at the scheduled expiration of the offer on August 14, 2007. The lawsuit seeking to require Lone Star to perform its obligations is scheduled for trial in the Delaware Court of Chancery beginning on September 26, 2007.
After Lone Star's August 10, 2007 announcement that it did not expect to accept Accredited shares tendered on August 14, 2007, Accredited filed the specific performance suit against Lone Star seeking to hold Lone Star to its obligations at $15.10 per share. James A. Konrath, chairman and chief executive officer of Accredited, commented, "Accredited has always believed that its case against Lone Star is very strong. Discovery has been proceeding in the lawsuit, and nothing we have seen to date has altered our perception of the strength of our case."
Accredited's Board of Directors had been meeting with the Company's litigation counsel and financial advisors on a regular basis to discuss the progress of the lawsuit and evaluate its merits. The Board of Directors believes Lone Star's proposal to reduce the tender offer price from $15.10 to $8.50 per share is not in the best interest of the shareholders and rejects it.
About Accredited
Accredited Home Lenders Holding Co. is a mortgage company operating throughout the U.S. and in Canada. Accredited originates, finances, securitizes, services, and sells non-prime mortgage loans secured by residential real estate. Founded in 1990, the company is headquartered in San Diego. Additional information may be found at www.accredhome.com.
Forward Looking Statements
This release contains forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934. These forward-looking statements involve a number of risks and uncertainties, including the Company's ability to close the proposed merger with Lone Star, to enforce Lone Star's obligation to close Lone Star's tender offer for the outstanding common stock of Accredited and to complete the merger with Accredited, and other risk factors as outlined in Accredited Home Lenders Holding Co.'s annual report on Form 10-K for the year ended December 31, 2006, and other documents filed by the Company with the Securities and Exchange Commission. These and other factors could cause the Company's actual results to differ materially from what it projects or contemplates in its forward-looking statements. The Company cautions readers that the non-prime mortgage industry and the Company's business are subject to numerous significant risks and uncertainties.
Contact:
Accredited Home Lenders Holding Co.
Rick Howe, 858.676.2148
http://biz.yahoo.com/bw/070831/20070831005480.html?.v=1
That will teach ya not to pick on our Miss Teen USA finalist, Lauren Caitlin Upton.LOL
KKSV 0.007(+75.00%)
Posted by: qrunq
In reply to: i_like_bb_stock who wrote msg# 1076039 Date:8/31/2007 8:15:00 AM
Post #of 1076043
LEND - lode star is on the hook for $15 and they know it. $6 trading price took into account that lode star was walking away. now the negotiation begins between 8.50 and 15. 10M shares are short.
LEND Extended Hours: Last 9.01 Change +2.70 (+42.79%)
(LOL) Miss Teen USA finalist, Lauren Caitlin Upton, offered a job at the White House as Bush's new political speechwriter
Written by Robert W. Armijo
Story written: 30 August 2007
Miss Teen USA's career advisor Washington, D.C. - Taken aback by the speech Miss Teen USA finalist, Lauren Caitlin Upton, gave at last Friday's competition, President Bush offered her a job as his official speechwriter.
The news came to Miss Upton by way of a personal phone call to her by President Bush late last night. However, not before Miss Upton's father hung up on him several times mistakenly believing it was a prank phone call until Cheney stepped in and made the call on behalf of the President before turning over the phone back to him.
"That's when we knew it was really the President calling and not a prank caller like I thought the half a dozen or so times when Bush first called," said Hank Upton, Miss Upton's father.
Upton father then handed the phone over to his beauty pageant daughter but not before asking Cheney how things were going over at the White House.
"Huh?" said Miss Upton. "I couldn't believe it was, umm, President…Oh, what's his name…Bush calling, er, me. And for, umm, a job as a speechwriter, too, Yak!"
Miss Upton says she credits her communication skills to her strict Christian moral up bring that her daddy gave her while she was growing up in South Carolina. There she attended church as a child on a regular bases, often speaking in tongues while she lead the church choir in song.
Her father only allowed her to read the Peanut comic strips and nothing else. Not even the Bible, fearing it would fill her head with impure thoughts.
"Yeah, but after daddy went to, er, sleep," said Miss Upton. "I cheated, uh, a little at night underneath my covers with my, umm, girlfriends. Why, we'd stay up all night long exploring each other's, uh, copies of Bloomfield County."
Reportedly, President Bush was watching Miss Teen USA when he heard Miss Upton's speech. It is said that he was so moved by her communications skills, he said it was like listening to himself speak, except he could finally understand what it was that he was trying to say to himself all these years.
No word on whether Miss Upton will accept the President's offer as she is said to be waiting by the phone for a better offer.
"I hear, umm, other agencies and corporations are interested in me, uh, as their spokesperson," said Miss Upton. "You know, like, uh, TSA, umm, FEMA, and together at the Mattel, uh."
The story above is a satire or parody. It is entirely fictitious.
If you fancy trying your hand at comedy spoof news writing, click here to join!
http://www.thespoof.com/news/spoof.cfm?headline=s2i24027
Thanks rover (I like that one better).
HOPE THIS IS WRONG: August 26, 2007
$4.5 billion options bet on catastrophe within four weeks
Anybody have a clue as to what these 'investors' are expecting?
The two sales are being referred to by market traders as "bin Laden trades" because only an event on the scale of 9-11 could make these short-sell options valuable.
There are 65,000 contracts @ $750.00 for the SPX 700 calls for open interest. That controls 6.5 million shares at $750 = $4.5 Billion. Not a single trade. But quite a bit of $$ on a contract that is 700 points away from current value. No one would buy that deep "in the money" calls. No reason to. So if they were sold looks like someone betting on massive dislocation. Lots of very strange option activity that I haven't seen before.
The entity or individual offering these sales can only make money if the market drops 30%-50% within the next four weeks. If the market does not drop, the entity or individual involved stands to lose over $1 billion just for engaging in these contracts!
Clearly, someone knows something big is going to happen BEFORE the options expire on Sept. 21.
THEORIES:
The following theories are being discussed widely within the stock and options markets today regarding the enormous and very unusual activity reported above and two stories below. Those theories are:
1) A massive terrorist attack is going to take place before Sept. 21 to tank the markets, OR;
2) China, reeling over losing $10 Billion in bad loans to the sub-prime mortgage collapse presently taking place, is going to dump US currency and tank all of Capitalism with a Communist financial revolution. Either scenario is bad and the clock is ticking. The drop-dead date of these contracts is September 21. Whatever is going to happen MUST take place between now and then or the folks involved in these contracts will lose over $1 billion for having engaged in this activity.
"$1.78 Billion Bet that Stock Markets will crash by third week in September Anonymous Stock Trader Sells 10K Contracts on EVERY S&P/Y "Strike" Shorts Stocks "in the money" effectively selling all his SPY holdings for cash up front without pressuring the market downward.
This is an enormous and dangerous stock option activity. If it goes right, the guy makes about $2 Billion. If he's wrong, his out of pocket costs for buying these options will exceed $700 Million!!! The entity who sold these contracts can only make money if the stock market totally crashes by the third week in September.
Bear in mind that the last time anyone conducted such large and unusual stock option trades (like this one) was in the weeks before the attacks of September 11.
Back then, they bought huge numbers of PUTS on airline stocks in the same airlines whose planes were involved in the September 11 attacks.
Despite knowing who made these trades, the Securities and Exchange Commission NEVER revealed who made the unusual trades and no one was ever publicly identified as being responsible for the trades which made upwards of $50 million when the attacks happened.
The fact that this latest activity by a single entity gambles on a complete collapse of the entire market by the third week in September, seems to indicate someone knows something really huge is in the works and they intend to profit almost $2 Billion within the next four weeks from whatever happens! This is really worrisome."
http://mparent7777-2.blogspot.com/2007/08/45b-bet-on-another-911-within-4-weeks.html
NO, that looks like someone thur 1000 of there own shares just hoping someone else will follow, so they can pick up shares cheap.
$0.12's printing
Looks like the longs dumped some: This should be a good starting point.
We'll know if it's to much later.LOL
(VSTR.PK 0.03)ValueSetters Announces Planned Merger Partner 30fold LLC
ValueSetters Inc., (VSTR.PK) the online buying group for independent retailers, today announced it is finalizing its merger plans with 30fold LLC, a privately held, Faith-Based Network Marketing Business headquartered in Arizona. The merged company, once completed, will continue as a publicly traded entity.
30fold currently hosts thousands of Online Christian Book and Music Stores and is in the process of expanding its product base to include health products, music instruments and giftware, whose supply is facilitated through ValueSetters. Sean Lee CEO of ValueSetters said, "The merger is a match made in Heaven as it allows the online bookstores to add a wide range of very profitable products to their line while giving ValueSetters a critical mass of resellers in the Christian community."
John Godzich, Founder and CEO of 30fold said, "We now have both the supply of profitable product and the audience for the product under one roof."
The company expects the merger to be completed in the next 30 days.
Forward-Looking Statements
The information contained herein includes certain forward-looking statements of our management. Forward-looking statements are statements that estimate the happening of future events and are not based on historical fact. Forward-looking statements may be identified by the use of forward-looking terminology, such as "may," "could," "expect," "estimate," "anticipate," "plan," "predict," "probable," "possible," "should," "continue," or similar terms, variations of those terms or the negative of those terms. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guaranty, or warranty is to be inferred from those forward-looking statements.
ValueSetters Inc., Phoenix
Sean Lee, 602-547-1611
slee@valuesetters.com
Source: Business Wire (August 30, 2007 - 6:11 AM EST)
just waiting for the news!!
XOMA (NASD, $2.79 +0.50pm) XOMA Licenses Antibody Technology to Pfizer
Tuesday, August 28 2007 - 8:05
BERKELEY, Calif., Aug. 28, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced that it has licensed to Pfizer Inc., the world's largest research-based biomedical and pharmaceutical company, non-exclusive, worldwide rights to XOMA's patented bacterial cell expression (BCE) technology for phage display and other research, development and manufacturing of antibody products.
Under the terms of the agreement, XOMA will receive an upfront, non-dilutive cash payment of $30 million and milestone, royalty and other fees on future sales of all products subject to this license, including products currently in late-stage clinical development.
Steven Engle, Chief Executive Officer and President of XOMA, said, "This agreement provides clear validation of XOMA's antibody research and affirms XOMA's ability to capitalize on the value of our patented technologies. We continue to execute our strategy of using our technologies to generate high-margin revenue in support of our programs, including our proprietary product pipeline. We are very pleased that Pfizer has chosen to incorporate our BCE technology into their global drug development effort, and we look forward to what we anticipate will be a mutually beneficial relationship.
"BCE is an enabling technology for antibody phage display discovery and for the manufacture of bacterially expressed therapeutic antibody products," Mr. Engle continued. "It is a proven technology for commercially significant therapeutic antibodies as demonstrated by the approval of LUCENTIS(r) for wet age-related macular degeneration. With more than 45 license agreements in place, BCE continues to be a seminal enabling technology in antibody discovery and production."
XOMA has licensed its BCE technology to many major pharmaceutical and biotechnology companies, including Merck & Co., Inc., Centocor, Inc. and Alexion Pharmaceuticals, Inc. for use in the development and manufacturing of marketed and investigational therapeutic antibody products. Under a license agreement with Genentech, Inc., XOMA currently receives royalties for their marketed therapeutic antibody product, LUCENTIS(r) which has been approved for the treatment of wet age-related macular degeneration since 2006. LUCENTIS(r) (ranibizumab) is an antibody fragment to Vascular Endothelial Growth Factor (VEGF). BCE technology is also employed for the production of CIMZIA (certolizumab, CDP-870), UCB S.A.'s anti-TNF (tumor necrosis factor) alpha antibody fragment, which has been submitted for regulatory approval for Crohn's disease. CIMZIA has had positive results in two Phase III trials in rheumatoid arthritis and in one mid-stage clinical trial in psoriasis.
XOMA plans to update 2007 revenue guidance to reflect the new agreement when it announces third quarter 2007 results.
Bacterial Cell Expression Technology
Bacterial cell expression technology (BCE) is an enabling technology used to discover and screen, as well as develop and manufacture, recombinant antibodies for commercial purposes. BCE is also a key technology used in multiple systems for high-throughput screening of antibody domains. Expression of antibodies by phage display technology, for example, depends on the expression and secretion of antibody domains from bacteria as properly folded, functional proteins.
XOMA scientists were the first to demonstrate the secretion of antibody domains directly from the bacterial cells as fully functional, properly folded molecules. XOMA has received ten U.S. patents to date relating to aspects of its BCE system, including six patents that broadly cover the secretion of immunoglobulins from bacteria, including antibody fragments such as Fab and single-chain antibodies. Corresponding foreign patents have also been granted. XOMA's intellectual property estate is applicable to the practice of antibody phage display and other antibody screening applications.
XOMA (NASD, $2.79 +0.50pm) XOMA Licenses Antibody Technology to Pfizer
Tuesday, August 28 2007 - 8:05
BERKELEY, Calif., Aug. 28, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced that it has licensed to Pfizer Inc., the world's largest research-based biomedical and pharmaceutical company, non-exclusive, worldwide rights to XOMA's patented bacterial cell expression (BCE) technology for phage display and other research, development and manufacturing of antibody products.
Under the terms of the agreement, XOMA will receive an upfront, non-dilutive cash payment of $30 million and milestone, royalty and other fees on future sales of all products subject to this license, including products currently in late-stage clinical development.
Steven Engle, Chief Executive Officer and President of XOMA, said, "This agreement provides clear validation of XOMA's antibody research and affirms XOMA's ability to capitalize on the value of our patented technologies. We continue to execute our strategy of using our technologies to generate high-margin revenue in support of our programs, including our proprietary product pipeline. We are very pleased that Pfizer has chosen to incorporate our BCE technology into their global drug development effort, and we look forward to what we anticipate will be a mutually beneficial relationship.
"BCE is an enabling technology for antibody phage display discovery and for the manufacture of bacterially expressed therapeutic antibody products," Mr. Engle continued. "It is a proven technology for commercially significant therapeutic antibodies as demonstrated by the approval of LUCENTIS(r) for wet age-related macular degeneration. With more than 45 license agreements in place, BCE continues to be a seminal enabling technology in antibody discovery and production."
XOMA has licensed its BCE technology to many major pharmaceutical and biotechnology companies, including Merck & Co., Inc., Centocor, Inc. and Alexion Pharmaceuticals, Inc. for use in the development and manufacturing of marketed and investigational therapeutic antibody products. Under a license agreement with Genentech, Inc., XOMA currently receives royalties for their marketed therapeutic antibody product, LUCENTIS(r) which has been approved for the treatment of wet age-related macular degeneration since 2006. LUCENTIS(r) (ranibizumab) is an antibody fragment to Vascular Endothelial Growth Factor (VEGF). BCE technology is also employed for the production of CIMZIA (certolizumab, CDP-870), UCB S.A.'s anti-TNF (tumor necrosis factor) alpha antibody fragment, which has been submitted for regulatory approval for Crohn's disease. CIMZIA has had positive results in two Phase III trials in rheumatoid arthritis and in one mid-stage clinical trial in psoriasis.
XOMA plans to update 2007 revenue guidance to reflect the new agreement when it announces third quarter 2007 results.
Bacterial Cell Expression Technology
Bacterial cell expression technology (BCE) is an enabling technology used to discover and screen, as well as develop and manufacture, recombinant antibodies for commercial purposes. BCE is also a key technology used in multiple systems for high-throughput screening of antibody domains. Expression of antibodies by phage display technology, for example, depends on the expression and secretion of antibody domains from bacteria as properly folded, functional proteins.
XOMA scientists were the first to demonstrate the secretion of antibody domains directly from the bacterial cells as fully functional, properly folded molecules. XOMA has received ten U.S. patents to date relating to aspects of its BCE system, including six patents that broadly cover the secretion of immunoglobulins from bacteria, including antibody fragments such as Fab and single-chain antibodies. Corresponding foreign patents have also been granted. XOMA's intellectual property estate is applicable to the practice of antibody phage display and other antibody screening applications.
(MINXX is protected under there INC.) Incorporation in the United States
Legal benefits
Protection of personal assets. Safeguarding personal assets against the claims of creditors and lawsuits. Sole proprietors and general partners in a partnership are personally and jointly responsible for all the liabilities of a business such as loans, accounts payable, and legal judgements. In a corporation, however, stockholders, directors and officers typically are not liable for their company's debts and obligations. They are limited in liability to the amount they have invested in the corporation (eg: If $100 in stock was purchased, no more than $100 can be lost). Corporations and Limited Liability Companies (LLCs) may also hold personal assets like houses, cars or boats. If one is personally involved in a lawsuit or bankruptcy, these assets may be protected. A creditor of the owner of a corporation or LLC cannot seize the assets of the company; however, they can seize their ownership shares in the corporation, as that is considered a personal asset.
Transferable ownership. Ownership in a corporation or LLC is easily transferable to others, either in whole or in part. Some states' laws are particularly attractive to this end. For example, with a Delaware Corporation, the transfer of ownership in a corporation is not required to be filed or recorded.
Retirement funds. Retirement funds.
Taxation. In the United States, corporations are taxed at a lower rate than individuals. Also, they can own shares in other corporations and receive corporate dividends 80% tax-free. There are no limits on the amount of losses a corporation may carry forward to subsequent tax years. A sole proprietorship, on the other hand, cannot claim a capital loss greater than $3,000 unless the owner has offsetting capital gains.
Raising funds through sale of stock. Capital from investors can be raised for corporations easily through the sale of stock.
Durability. A corporation is capable of continuing indefinitely. Its existence is not affected by the death of shareholders, directors, or officers of the corporation.
Credit rating. Regardless of an owner's personal credit scores, corporations acquire their own credit rating, and build a separate credit history by applying for and using corporate credit http://en.wikipedia.org/wiki/Incorporation_(business)
(JDMC 1@ $0.03)WEEEEE, will this ever trade in the thousands? or even hundreds?
(JDMC)Type: Fee
Account: etrade
Date posted: 08/23/2007
Amount: $20.00
Description: JADE MOUNTAIN CORPORATION MANDATORY REORG FEE
Jack check out DVNNF .14 +82% VOLUME 169,250 something is up.
DVNNF .14 +82% VOLUME 169,250 something is up.
Sorry for the double post,I got all excited when I saw our friend back in.ZIPL, WEEEEEE
WOW you bought those 500 shares that printed at 0.04 LOL, you go big spender..GOOD to have you back or did you dump it at 0.05 due to the BIG MELT DOWN,,LOL
WOW you bought those 500 shares that printed at 0.04 LOL, you go big spender..GOOD to have you back or did you dump it at 0.05 due to the BIG MELT DOWN,,LOL
DVNNF Last: 0.12 Change: +0.043(+55.84%) Volume: 70.0 k
0.06's up to bat THDS
THDS 0.049 PRINTING
THANKS FOR THE 0.033's
SSP You still da DD man in my book..Keep up the GOOD work..
Ya, no rush I just had enough of etrade looking at other brokers..
And what other message board would that be? When copying another post you should copy the whole thing..Posted by: jerseyshore
In reply to: None Date:8/21/2007 9:25:52 AM
Post #of 1605
Just spoke with Allen from pinksheets.com He is very aware or Ziplinks, he is the one that removed Minxx from pinksheets..He FIRMLY STATED D.R. ENTERTAINMENT in Nevada is the owner of the shell (stated there is NO company Ziplink) Pinksheets is waiting for the NASD to issue the new name/symbol/cuspid #..when he receives them he will post them..I asked did you prematurely post the Minxx info..He stated the attorney contacted pinksheets and told then take it down..Please call pinksheets they are VERY friendly and willing to answer all questions 212-896-4420 http://www.pinksheets.com/pink/quote/quote.jsp?symbol=zipl#getFilings
(JDMC)-ETRADE:From: E*TRADE Customer Service
Sent: August 22, 2007 9:15 AM ET
Subject: Portfolio
Topic: Reorganizations
Account: XXXX
Dear Mr.XXXX
Thank you for your message regarding your position in JDMC. I apologize for the confusion this has caused. I do see that this position went through a reverse split back on 7/17/07, but I no longer see the shares in your account. I have submitted a request to our corporate actions department to research this situation. They should have a response back in 2-3 business days. Please check back with us after that timeframe is up and we should be able to provide you some further information. If you have any further questions, please contact us.
I hope this information has been helpful. Please let us know if we've addressed your questions and concerns satisfactorily by taking a 30-second survey at the following web address:
Sincerely, Wesley Merritt
Financial Services Representative
Lets let it go.Do some of you think KRUNK STOXXX could control the price of ZIPL,COME ON, the bathroom attendant at MINXX has more control of this stock..I did enough DD on this to know what I am holding.If thats the way KRUNK STOXXX feels BIG DEAL..ZIPL will be at $$$ soon..jmo
TD Ameritrade and E*Trade in merger talks: reportNEW YORK (Reuters) - Online brokerages TD Ameritrade Holding Corp (AMTD.O: Quote, Profile, Research) and E*Trade Financial Corp (ETFC.O: Quote, Profile, Research) have been in serious merger discussions for weeks but are not yet close to a deal, the Wall Street Journal reported.
The paper's Web site, which early on Wednesday cited people familiar with the matter, said consolidation of the two giants could shake up the industry, which went through a wave of consolidation after the dot.com bubble burst, by creating a dominant player.
It said E*Trade and TD Ameritrade together could eclipse Charles Schwab Corp (SCHW.O: Quote, Profile, Research), currently the largest online brokerage.
The merger could also reduce some of the fierce competition typical of the industry, which has driven down the cost of online trading while squeezing the sector's profit margins, the Journal said.
"We do believe that consolidation provides tremendous opportunity: If there is an alignment in strategy and product we do see value," Mathias Helleu, managing director of E*Trade's international operations, told Reuters in Singapore, adding the company does not comment on specific rumors.
TD Ameritrade could not immediately be reached for comment.
As of the end of June, E*Trade counted 4.7 million brokerage and banking accounts compared with 6.3 million such accounts at TD Ameritrade, and 6.9 million at Charles Schwab Corp, the Journal reported. In contrast, Merrill Lynch & Co., (MER.N: Quote, Profile, Research) has more than 7 million customer accounts.
A TD Ameritrade spokeswoman told the newspaper, "We have talked and continue to talk to peers in the industry."
The most recent round of talks -- with both companies having discussed joining together several times in past years -- come as two hedge funds with big stakes in TD Ameritrade publicly called on the two companies to talk, according to the Journal.
The two funds, Jana Partners LLC and SAC Capital, successfully pushed TD Ameritrade to drop its CEO from a committee considering merger and acquisition opportunities in favor of independent members.
Jana and SAC, which together own about 8.4 percent of TD Ameritrade, have consistently said merger discussions must be free of the influence of Toronto-Dominion Bank (TD.TO: Quote, Profile, Research), which owns about 40 percent of the brokerage.
The value of a merger deal between E*Trade and TD Ameritrade, or how it would be structured, were not clear, according to the Journal.
However, one person familiar with the talks estimated a deal could value the combined company at as much as $20 billion, according to the newspaper, taking into account the possible savings from merging company accounts on to a single computer system.
TD Ameritrade and E*Trade's talks are currently centered around whether the two firms agree on strategy, according to the report, citing a source.
Recent turbulence in credit markets has added to the issues under review, with E*Trade last week being hit by concerns over the quality of its mortgage portfolio.
Shares of E*Trade fell as much as 28 percent last Thursday, but recovered on Friday after the company reassured investors about the credit quality of its mortgage holdings.
E*Trade shares closed up 6.35 percent to $15.57 on Nasdaq on Tuesday, while Ameritrade shares gained one percent to close at
$16.35.http://www.reuters.com/article/businessNews/idUSL2269053420070822?feedType=RSS&feedName=business...
Dog Bites Off Man’s Genitals. A police report concerning the dog that apparently bit off a man’s genitals says that the man may have been using force against the animal.
Rudolfo Ramirez, 25, might have been trying to forcibly open the pit bull’s mouth. [..]
“As soon as he hit the dog, the dog yelped and the guy got up,” Chacon remembers. “He was still alive but his inner thighs, genitalia, and lower stomach was all ripped away.”
Chacon said Ramirez didn’t say a word and ran away as police approached, but he was caught at a nearby park.’
followup to Dog Bites Off Man’s Genitals.
http://www.moonbuggy.org/archive/2004/09/12/dog-who-bit-off-mans-penis-might-have-been-provoked/
Thanks Bob41 I sent it along with a few choice words.
If you don't throw it at the bid you can't get out.I guess all Etrade customers would be bid wackers.LOL